



Pharmobedient Consulting, LLC
642 N.E. 3rd Avenue
Fort Lauderdale, FL 33304
Attn: Anthony LaViola

Sent via email to: anthony@pharmobedient.com

Docket No. FDA-2024-P-2778

Dear Anthony LaViola:

This is in response to your petition received on June 7, 2024, by the U.S. Food and Drug Administration (FDA or Agency) and your amendment dated June 28, 2024, requesting permission to submit an Abbreviated New Drug Application (ANDA) for the following drug products: Chlorzoxazone Orally Disintegrating Tablets (ODT), 250 mg and 500 mg. The listed drug product to which you refer in your petition is Paraфон Forte DSC (Chlorzoxazone) Tablets, 500 mg approved under NDA 011529 and held by Janssen Research and Development, LLC.

Your request involves a change in strength and dosage form from that of the listed drug product (i.e., from Chlorzoxazone 500 mg oral tablets to Chlorzoxazone Orally Disintegrating Tablets (ODT), 250 mg and 500 mg). The changes that you request are the type of changes that are permissible under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (Act), subject to FDA approval of a petition submitted under that section of the Act. However, for the reasons explained below, the Agency denies your request.

We have reviewed your petition under section 505(j)(2)(C) of the Act and FDA's implementing regulations at 21 CFR 314.93. FDA will approve a petition properly submitted under § 314.93 unless FDA finds, among other grounds for denying such a petition, investigations must be conducted to show the safety and effectiveness of the drug product or of any of its active ingredients, its route of administration, dosage form, or strength which differs from the reference listed drug. See section 505(j)(2)(C) of the Act; 21 CFR 314.93(e)(1)(i).

In addition, the Pediatric Research Equity Act (PREA) provides that a person who submits an application or supplement under section 505 for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration shall submit assessments adequate to evaluate the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration in each pediatric subpopulation for which the drug is safe and effective, unless this requirement is waived. Section 505B of the Act. If a change proposed in a suitability petition triggers the need for pediatric studies under PREA to assess safety and efficacy in a relevant pediatric subpopulation and FDA does not waive the requirement,

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov



the proposed product will not be eligible to be approved in an ANDA and the suitability petition must be denied. See section 505(j)(2)(A) of the Act ("The Secretary may not require that an abbreviated application contain information in addition to that required by clauses (i) through (viii) [of Section 505(j)(2)(A)]."). Because you are seeking a change in dosage form, this proposed product triggers PREA.

The Agency has determined that clinical trials are required under PREA because there may be a meaningful benefit for this drug product in children 12 years of age and older.

Therefore, this petition is being denied because clinical trials are required under PREA for the approval of the requested change to the drug product. The request for a full waiver of the pediatric study requirements under PREA has been denied. Please contact the Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP) at (301) 796 - 2280 if you wish to pursue approval of your product under section 505(b) of the Act.

If you disagree with our determination concerning the approvability of your petition as originally submitted, you may seek a reconsideration of the denial following the procedures set forth in 21 CFR 10.33. Requests for reconsideration must be based solely on the information contained in your original petition and must be submitted in accordance with 21 CFR 10.20, in the format outlined in § 10.33 and no later than 30 days after the date of the decision involved. Petitions for reconsideration should be filed with the Dockets Management Branch at the address listed below. If there is additional information, not included as part of your original submission that you would like the Agency to consider, you should submit a new petition including all the necessary information to the Dockets Management Branch.

A copy of this letter denying your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely,

William Chong, M.D.
Director
Office of Safety and Clinical Evaluation
for Lilun Murphy, M.D.
Director
Office of Generic Drugs
Center for Drug Evaluation and Research



William
Chong

Digitally signed by William Chong

Date: 12/23/2024 09:43:14AM

GUID: 508da7450002bdd54805b3a331b19b0d